Background This guideline has been developed jointly by the European Society of
Haematology and International Society of Amyloidosis recommending non-transplant …

Systemic light-chain (AL) amyloidosis is caused by a small B cell, most commonly a plasma
cell (PC), clone that produces toxic light chains (LC) that cause organ dysfunction and …

Chimeric antigen receptor (CAR)-T cell therapy has shown remarkable clinical efficacy
against B-cell malignancies, yet marked vulnerability to antigen escape and tumor relapse …

Purpose: AL amyloidosis (AL) treatments are generally based on those employed for
multiple myeloma. Anti–B-cell maturation antigen (BCMA) chimeric antigen receptor T …

Systemic light chain (AL) amyloidosis is a rare clonal plasma cell disorder characterized by
the production of amyloidogenic immunoglobulin light chains, which causes the formation …

Bispecific T cell engaging antibodies (bsAbs) have emerged as novel and powerful
therapeutic agents for redirecting T cells towards antigen-specific tumor killing. The cell …

Multiple myeloma (MM) is still an incurable disorder despite improved antibody and cellular
therapies against different MM antigens. Single targeted antigens have so far been …

Despite significant breakthroughs in the understanding of immunological and
pathophysiological features for immune-mediated kidney diseases, a proportion of patients …

Immunotherapy has changed treatment practices for many hematologic malignancies. Even
in the current era of targeted therapy, chemotherapy remains the backbone of treatment for …

Opinion Statement Light-chain amyloidosis is a rare disorder where a small clone of plasma
cells is producing excess toxic light chains that deposit in various organs and cause …